Metraipolis › archive › dc_39bc15d04432
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection — Europe PMC PMID:41854512
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41854512
- DOI
- 10.1093/oncolo/oyag085
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T11:32:00.118Z
- SHA-256 of the archived text
931d3e2387d911d95ee28c84692b68142c05d12099d484217c2ec11a96dd4180- Stable URL of this page
https://metraipolis.com/documento/dc_39bc15d04432
How to cite
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection — Europe PMC PMID:41854512 — Europe PMC (en), https://europepmc.org/article/MED/41854512 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_39bc15d04432 (Metraipolis archive dc_39bc15d04432, sha256 931d3e2387d911d95ee28c84692b68142c05d12099d484217c2ec11a96dd4180)
BibTeX
@misc{dc39bc15d04432,
title = {Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection — Europe PMC PMID:41854512},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41854512},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_39bc15d04432; sha256 931d3e2387d911d95ee28c84692b68142c05d12099d484217c2ec11a96dd4180},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41854512. Agents can read the archived copy with the MCP tool read_document.